References
- The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease, II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984: 251(3)-351–64-251(3): 365–74
- The Pooling Project Research Group. Relationship of blood pressure, serum cholesterol. smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling project. J Chronic Dis 1978: 31(4): 201–306
- Siegel D, Grady D, Browner WS, et al. Risk factor modification after myocardial infarction. Ann Intern Med 1988: 109(3): 213–8
- Detrano R, Froelicher V. A logical approach to screening for coronary artery disease. Ann Intern Med 1987: 106(6): 846–52
- Friedewald WT, Furberg CD, May GS. Cardiovasc Rev Rep 1984: 5: 1285–9
- Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med 1985: 313(22): 1369–75
- The Steering Committee of the Physicians' Health Study Research Group. Preliminary report: findings from the aspirin component of the ongoing physicians' health study. N Engl J Med 1988: 318(4): 262–4
- Br Med J 1988: 296: 313
- Lee TH, Rouan GW, Weisberg MC, et al. Sensitivity of routine clinical criteria for diagnosing myocardial infarction within 24 hours of hospitalization. Ann Intern Med 1987: 106(2): 181–6
- Gruppo Italiano per lo Studio della Streptochl-nasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986: 1: 397–401
- ISIS Steering Committee. Intravenous streptokinase given within 0–4 hours of onset of myocardial infarction reduced mortality in ISIS-2. (Letter) Lancet 1987: 1(8531): 502
- TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase I findings. N Engl J Med 1985: 312(14): 932–6
- Verstraete M, Bernard R, Bory M, et al. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction: report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. Lancet 1985: 1(8433): 842–7
- The I.S.A.M. Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM). N Engl J Med 1986: 314(3): 1465–71
- Stadius ML, Davis K, Maynard C, et al. Risk stratification for 1 year survival based on characteristics identified in the early hours of acute myocardial infarction: the Western Washington Intracoronary Streptokinase Trial. Circulation 1986: 74(4): 703–11
- White H, Brown M, Takayama M, et al. Improved left ventricular function and early survival with intravenous streptokinase. Circulation 1986: 74(Suppl II): II–5
- American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures. Guidelines for percutaneous transluminal coronary angioplasty. Circulation 1988: 78: 486–502
- O'Neill W, Timmis GC, Bourdillon PD, et al. A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. N Engl J Med 1986: 314(13): 812–8
- Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987: 317(10): 581–8
- Simoons ML, Arnold AE, Betriu A, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988: 1(8579): 197–203
- Cohn LH. Surgical treatment of acute myocardial infarction. Chest 1988: 93(Suppl 1): 13–6S
- Woosley RL. Indications for antiarrhythmic therapy: a wealth of controversy, a dearth of data. Ann Intern Med 1988: 108(3): 450–2